(12) International Application Status Report

Received at International Bureau: 13 March 2018 (13.03.2018)

Information valid as of: 04 February 2019 (04.02.2019)

Report generated on: 26 January 2020 (26.01.2020)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2018/16457313 September 2018 (13.09.2018) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/NL2018/05013706 March 2018 (06.03.2018) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
17159420.3 (EP)06 March 2017 (06.03.2017) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
A61K 38/55 (2006.01); A61P 31/14 (2006.01)

(71) Applicant(s):
ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC [NL/NL]; Albinusdreef 2 2333 ZA Leiden (NL) (for all designated states)
THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO [CA/CA]; 27 King's College Circle Toronto, Ontario M5S 1A1 (CA) (for all designated states)
UNIVERSITY OF MANITOBA [CA/CA]; 207 Administration Building Winnipeg, Manitoba R3T 2N2 (CA) (for all designated states)

(72) Inventor(s):
KIKKERT, Marjolein; c/o Albinusdreef 2 2333 ZA Leiden (NL)
KNAAP, Robert Cornells Martinus; c/o Albinusdreef 2 2333 ZA Leiden (NL)
SIDHU, Sachdev Singh; c/o The Donnelly Centre for Cellular and Biomolecular Research University of Toronto Room 816, 160 College Street Toronto Ontario M5S3E1 (CA)
ZHANG, Wei; c/o The Donnelly Centre for Cellular and Biomolecular Research University of Toronto Room 816, 160 College Street Toronto, Ontario M5S3E1 (CA)
MARK, Brian Leonard; c/o Department of Microbiology University of Manitoba 127 Buller Building Winnipeg, Manitoba R3T 2N2 (CA)
BAILEY-ELKIN, Ben Allan; c/o Department of Microbiology University of Manitoba 127 Buller Building Winnipeg, Manitoba R3T 2N2 (CA)

(74) Agent(s):
JANSEN, CM.; V.O. Carnegieplein 5 2517 KJ Den Haag (NL)

(54) Title (EN): VIRAL POLYPEPTIDE INHIBITORS
(54) Title (FR): INHIBITEURS DE POLYPEPTIDES VIRAUX

(57) Abstract:
(EN): The disclosure provides polypeptide inhibitors of viral proteins, useful in the treatment and prevention of viral infection. The viral inhibitors are particularly useful for treating Middle East respiratory syndrome coronaviral (MERS-CoV) infection, Crimean-Congo hemorrhagic fever viral infection, or the symptoms of infection.
(FR): L'invention concerne des inhibiteurs polypeptidiques de protéines virales, utiles dans le traitement et la prévention d'une infection virale. Les inhibiteurs viraux sont particulièrement utiles pour traiter une infection par le coronavirus du syndrome respiratoire du Moyen-Orient (MERS-CoV), une infection virale de la fièvre hémorragique de Crimée-Congo, ou les symptômes d'une infection.

International search report:
Received at International Bureau: 27 August 2018 (27.08.2018) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:
Not available

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM